Oxford Biomedica
Result of Annual General Meeting
Oxford, UK - 24 June 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 24 June 2024 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxb.com
Copies of the document setting out the above resolutions passed at the 2024 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
On the Record Date (20 June 2024) there were 105,268,630 ordinary shares of 50 pence each in issue, each carrying one vote per share.
|
|
Resolution |
Votes For (incl. votes at the Chairman's discretion) |
% of votes cast |
Votes Against |
|
Votes Withheld* |
Total votes cast | Result |
|
|
|
|
|
|
|
|
|
|
|
| Ordinary resolutions | | | | | | | |
| | | | | | | | | |
|
1
| To receive and adopt the Company's Annual Report and accounts for the financial year ended 31 December 2023, the Directors' Report, and the Report of the Independent Auditors on those accounts and reports. | 72,477,617 | 99.99% | 4,552 | 0.01% | 608,560 | 72,482,169 | PASS
|
|
2
| To receive the Directors' Remuneration Report and the Report of the Independent Auditors on the auditable part of the Remuneration Report (excluding the Directors' Remuneration Policy) for the financial year ended 31 December 2023. | 72,347,034 | 99.61% | 280,462 | 0.39% | 463,233 | 72,627,496 | PASS
|
|
3
| To consider and, if thought fit, approve the Directors' Remuneration Policy, the full text of which is included in the Directors' Remuneration Report for the financial year ended 31 December 2023. | 70,899,498 | 97.67% | 1,691,080 | 2.33% | 500,151 | 72,590,578 | PASS
|
|
4
| To appoint Peter Soelkner as a Director of the Company. | 72,622,493 | 99.98% | 11,817 | 0.02% | 456,419 | 72,634,310 | PASS
|
|
5
| To reappoint Dr. Roch Doliveux as a Director of the Company. | 72,614,517 | 99.97% | 18,800 | 0.03% | 457,412 | 72,633,317 | PASS
|
|
6 | To reappoint Stuart Henderson as a Director of the Company. | 72,621,001 | 99.98% | 13,309 | 0.02% | 456,419 | 72,634,310 | PASS
|
|
7
| To reappoint Professor Dame Kay Davies as a Director of the Company. | 72,619,922 | 99.98% | 13,395 | 0.02% | 457,412 | 72,633,317 | PASS
|
|
8
| To reappoint Dr. Frank Mathias as a Director of the Company. | 72,623,288 | 99.99% | 10,522 | 0.01% | 456,919 | 72,633,810 | PASS
|
|
9
| To reappoint Stuart Paynter as a Director of the Company. | 72,623,118 | 99.99% | 10,199 | 0.01% | 457,412 | 72,633,317 | PASS
|
|
10
| To reappoint Robert Ghenchev as a Director of the Company. | 72,585,321 | 99.93% | 47,996 | 0.07% | 457,412 | 72,633,317 | PASS
|
|
11
| To reappoint Namrata Patel as a Director of the Company. | 72,619,735 | 99.98% | 13,582 | 0.02% | 457,412 | 72,633,317 | PASS
|
|
12
| To reappoint Leone Patterson as a Director of the Company. | 71,427,129 | 98.34% | 1,206,006 | 1.66% | 457,594 | 72,633,135 | PASS
|
|
13
| To reappoint Dr. Heather Preston as a Director of the Company. | 71,207,370 | 98.04% | 1,425,964 | 1.96% | 457,395 | 72,633,334 | PASS
|
|
14
| To appoint PricewaterhouseCoopers LLP as auditors of the Company from the conclusion of the meeting until the conclusion of the next AGM of the Company at which the accounts are laid. | 72,579,009 | 99.98% | 16,159 | 0.02% | 495,561 | 72,595,168 | PASS
|
|
15
| To authorise the Audit Committee for and on behalf of the Board to determine the auditor's remuneration. | 72,580,492 | 99.98% | 15,389 | 0.02% | 494,848 | 72,595,881 | PASS
|
|
16 | To approve the Oxford Biomedica 2024 Long Term Incentive Plan. | 62,538,002 | 86.10% | 10,095,007 | 13.90% | 457,720 | 72,633,009 | PASS
|
|
17
| To approve the Oxford Biomedica 2024 Deferred Bonus Plan. | 62,775,222 | 86.43% | 9,856,415 | 13.57% | 459,092 | 72,631,637 | PASS
|
|
18
| To approve the Oxford Biomedica 2024 Sharesave Scheme. | 63,225,470 | 87.05% | 9,408,593 | 12.95% | 456,666 | 72,634,063 | PASS
|
|
19
| To authorise the Directors to allot shares. | 72,168,633 | 99.41% | 426,961 | 0.59% | 495,135 | 72,595,594 | PASS
|
|
20
| To authorise the Directors to disapply pre-emption rights. | 72,215,940 | 99.48% | 378,341 | 0.52% | 496,448 | 72,594,281 | PASS
|
|
21
| To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments. | 72,215,440 | 99.48% | 378,841 | 0.52% | 496,448 | 72,594,281 | PASS
|
|
22
| To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice. | 72,369,632 | 99.63% | 265,377 | 0.37% | 455,720 | 72,635,009 | PASS
|
* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.
In addition, further to the announcement by the Company on 11 March 2024, Dr. Michael Hayden and Catherine Moukheibir have stepped down from the Company's Board of Directors with effect from the conclusion of today's AGM.
-Ends-
| For further information, please contact: | |
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
ABOUT OXFORD BIOMEDICA
Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.